INTERNATIONAL FLAVORS & FRAGRANCES INC (IFF) stock intrinsic value fair value estimate & owner earnings analysis

International Flavors & Fragrances makes the flavors, fragrances and biological ingredients (enzymes, probiotics, cultures) that consumer-goods companies build into foods, drinks, detergents, perfumes and supplements. Once a flavor or fragrance is designed into a customer's product, switching suppliers means reformulating and re-testing, which makes revenue sticky; the industry is dominated by four large players. IFF has been reshaped repeatedly: it bought Frutarom in 2018, merged with DuPont's Nutrition & Biosciences business in 2021 (more than doubling the share count to about 255 million and lifting long-term debt from about $3.8 billion to about $10.8 billion), then wrote off about $6 billion of goodwill between 2022 and 2025 and began selling businesses. It sold Pharma Solutions in May 2025, and on May 29, 2026 agreed to sell Food Ingredients to CVC Capital Partners for about $4.3 billion, with roughly $3.8 billion of net cash plus a retained stake of about 10% (about $200 million), closing expected by the end of the second quarter of 2027. We value what remains: Taste, Scent, and Health & Biosciences. How we measured earnings. We start from operating cash flow, remove year-to-year working-capital swings, deduct stock compensation as a real cost, and deduct capital spending (treated as all maintenance, since sales have been falling). Amortization of acquired intangibles (about $568 million in 2025) and the goodwill write-offs are non-cash and are not deducted; the ongoing cost of replacing what they represent is already paid through research and selling expenses. Because we value the business before its lenders, interest paid is added back and the debt is subtracted separately. On that basis the whole company produced about $700 million of cash before interest in 2023, $924 million in 2024 and $818 million in 2025. The company does not report cash flow by segment, so we removed Food Ingredients and Pharma Solutions using their reported segment EBITDA less their segment capital spending less an estimated 22% tax: Food Ingredients contributed roughly $136 to $181 million a year (its EBITDA of $423 million in 2025 was absorbed largely by $223 million of capital spending), and Pharma about $22 to $88 million. What remains, which keeps all corporate overhead, earned about $489 million in 2023 (an industry-wide customer destocking year with heavy tax payments), $655 million in 2024 and $660 million in 2025. We use the median of those three years, about $655 million or roughly $2.55 per share, as the starting level. Years before 2023 included businesses since sold and a 2021-2022 pricing peak, so they do not describe today's company. Cash from the continuing business grew about 1% in 2025; our base case assumes 0.5% in the first year, and also deducts about $50 million a year for higher equipment spending, since management says capital spending in 2026 will be about 6% of sales. What it owes. At June 30, 2026 IFF had about $5.70 billion of debt and $569 million of cash. Much of that debt is fixed at low rates for many years: $804 million of 2027 notes at 1.83%, $1.24 billion of 2030 notes at 2.30%, and long bonds due 2040 to 2050 at roughly 3.3% to 5.0%. Borrowing that cheap is worth about $730 million to shareholders compared with paying a full 6% rate. Adding the Food Ingredients proceeds (discounted to the expected closing), the retained stake and that business's cash until closing (about $3.94 billion together), and subtracting about $33 million of outside owners' interests, leaves net obligations of only about $0.5 billion once the sale closes. Bear case: a repeat of the 2023 destocking cuts cash to about $370 million in the first year, the step-up in capital spending (about $117 million a year) proves permanent, share losses to larger rivals offset all price increases for a decade, and earnings then shrink 1% a year. It also charges $300 million for fines or settlements from the European, UK, Swiss and Mexican competition investigations into fragrance pricing that began in March 2023 (the U.S. Justice Department closed its inquiry in February 2026 and IFF has applied for leniency). The business is worth about $7.7 billion; after about $0.5 billion of net obligations, the shares are worth about $28. Even here the business comfortably covers its interest bill. Base case: cash is about $608 million in the first year after the higher capital spending, then grows 2% a year for ten years as price increases keep pace with costs, and holds flat after that, supported by the embedded customer formulations and the ongoing research spending that has sustained the business through decades of competition. It charges $100 million for the competition investigations. The business is worth about $11.5 billion; after $0.5 billion of net obligations, about $43 per share. Bull case: the improvement visible in the first half of 2026 (operating cash flow of $679 million versus $368 million a year earlier, on similar capital spending) holds, giving about 6% growth in the first year, then 3.5% a year through year ten as pricing power and the cost program continue, and 2% a year through year twenty before leveling off. The business is worth about $16.2 billion; after $0.5 billion of net obligations, about $61 per share. Growth we left out: management's margin targets, new markets, and any return to the higher 2021-2022 earnings levels, none of which is secured. Share buybacks promised from the sale proceeds are not counted. What has changed. Our previous analysis put the base case near $24 and showed the shares worth nothing in a bad outcome. Three things move the estimate up: the signed Food Ingredients sale converts a capital-hungry business generating perhaps $150 million of cash a year into about $3.8 billion of cash for debt reduction; we now discount every case at the same 6% rate and carry the risk inside the cases, rather than using a higher rate for the risky ones; and we now credit the value of IFF's long, cheap fixed-rate bonds. Our starting earnings level is actually slightly lower than before. What would make this wrong: the Food Ingredients sale failing to close (worth roughly $5 to $6 per share); capital spending staying near 6% of sales without producing growth; proceeds being spent on another large acquisition, repeating the pattern of the Frutarom and DuPont deals; or competition fines far larger than assumed. The cash contributions of the sold businesses are our estimates from segment data rather than reported figures.